{"answer":{"query":"imbruvica","resolved_as":"name","packages":8,"applications":["NDA205552","NDA210563","NDA217003"],"identity":{"application_numbers":["NDA205552","NDA210563","NDA217003"],"marketing_categories":["NDA"],"labelers":[{"text":"PHARMACYCLICS, LLC.","untrusted":true}],"dosage_forms":[{"text":"SUSPENSION","untrusted":true},{"text":"TABLET, FILM COATED","untrusted":true},{"text":"CAPSULE","untrusted":true}],"marketing_start":{"earliest":"2013-11-13","latest":"2022-08-24","packages_with_a_start_date":7}},"price":{"median_negotiated_over_nadac":null,"packages_compared":0,"packages_listed":8,"negotiated_price_ends":null,"rows":[{"ndc":"57962000712","name":{"text":"IMBRUVICA (ibrutinib) 70mg/mL Oral Suspension","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":59.130971,"ratio":null,"ful_per_unit":null},{"ndc":"57962001428","name":{"text":"IMBRUVICA (ibrutinib) 140mg Tablets 28 ct.","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":353.928391,"ratio":null,"ful_per_unit":null},{"ndc":"57962007028","name":{"text":"IMBRUVICA (ibrutinib) 70mg Capsules 28 ct.","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":354.002614,"ratio":null,"ful_per_unit":null},{"ndc":"57962014009","name":{"text":"IMBRUVICA (ibrutinib) 140mg 90 ct.","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":118.000977,"ratio":null,"ful_per_unit":null},{"ndc":"57962014012","name":{"text":"IMBRUVICA (ibrutinib) 140mg 120 ct.","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":118.000977,"ratio":null,"ful_per_unit":null},{"ndc":"57962028028","name":{"text":"IMBRUVICA (ibrutinib) 280mg Tablets 28 ct.","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":353.939996,"ratio":null,"ful_per_unit":null},{"ndc":"57962042028","name":{"text":"IMBRUVICA (ibrutinib) 420mg Tablets 28 ct.","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":353.977199,"ratio":null,"ful_per_unit":null},{"ndc":"57962056028","name":{"text":"IMBRUVICA (ibrutinib) 560mg Tablets 28 ct.","untrusted":true},"class":null,"nadac_per_unit":null,"negotiated_per_unit":353.963176,"ratio":null,"ful_per_unit":null}],"negotiated_scheduled":{"thirty_day":9571.07,"effective":"2027-01-01"}},"generic_entry":[{"application":"NDA205552","date":"2035-04-24","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10463668*PED","productNo":"001"},"latest_patent_expiry":"2035-04-24","latest_exclusivity_expiry":"2030-02-24","dated_barriers":140,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":34,"exclusivities_listed":4,"fact_id":"72bc056f0f3ee5c5d9b5c588"},{"application":"NDA210563","date":"2036-09-03","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"10010507*PED","productNo":"001"},"latest_patent_expiry":"2036-09-03","latest_exclusivity_expiry":"2030-02-24","dated_barriers":286,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":38,"exclusivities_listed":4,"fact_id":"273ffd5052bd46666a6e35fc"},{"application":"NDA217003","date":"2039-06-14","reading":"upper bound from listed dates, not a forecast","basis":"latest of all listed patent and exclusivity expiries in this Orange Book edition; an upper bound from listed dates only, not a forecast of launch (litigation, settlements, delisting, tentative approvals and 180-day status are not modelled)","driver":{"kind":"patent","ref":"12201690","productNo":"001"},"latest_patent_expiry":"2039-06-14","latest_exclusivity_expiry":"2030-02-24","dated_barriers":50,"undated_barriers":0,"orange_book_edition":"2026-09","patents_listed":31,"exclusivities_listed":4,"fact_id":"314fd667a1a05f5fe53dc891"}],"label_history":{"events_total":55,"non_cmc_events":46,"counts_by_class":{"LABELING":22,"EFFICACY":24},"cmc_events":9,"recent_non_cmc_events":[{"application":"NDA205552","submission_no":44,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-21","documents":[{"type":"Label","date":"2025-10-22","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205552s044,210563s020,217003s005lbl.pdf","untrusted":true}},{"type":"Letter","date":"2025-10-23","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/205552Orig1s044;210563Orig1s020;217003Orig1s005ltr.pdf","untrusted":true}}],"fact_id":"4094080b1fa4812875667e33"},{"application":"NDA210563","submission_no":20,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-21","documents":[{"type":"Letter","date":"2025-10-23","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/205552Orig1s044;210563Orig1s020;217003Orig1s005ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-10-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205552s044,210563s020,217003s005lbl.pdf","untrusted":true}}],"fact_id":"272f75ee5d3085cd138cb917"},{"application":"NDA217003","submission_no":5,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2025-10-21","documents":[{"type":"Letter","date":"2025-10-23","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/205552Orig1s044;210563Orig1s020;217003Orig1s005ltr.pdf","untrusted":true}},{"type":"Label","date":"2025-10-31","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205552s044,210563s020,217003s005lbl.pdf","untrusted":true}}],"fact_id":"884466885eda792037cc80ab"},{"application":"NDA205552","submission_no":43,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-12-20","documents":[{"type":"Letter","date":"2024-12-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/205552Orig1s043,210563Orig1s019,217003Orig1s004ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-12-26","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205552s043,210563s019,217003s004lbl.pdf","untrusted":true}}],"fact_id":"4e25f062f05acbb3ee0854fe"},{"application":"NDA210563","submission_no":19,"class_code":"LABELING","class_description":{"text":"Labeling","untrusted":true},"status":"AP","date":"2024-12-20","documents":[{"type":"Letter","date":"2024-12-26","link":{"text":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/205552Orig1s043,210563Orig1s019,217003Orig1s004ltr.pdf","untrusted":true}},{"type":"Label","date":"2024-12-26","link":{"text":"http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/205552s043,210563s019,217003s004lbl.pdf","untrusted":true}}],"fact_id":"b158d508679ddafa552e06c1"}],"note":"a dated list of FDA supplements and their classes, not a reading of what changed in the label"},"substitution":{"products_total":13,"te_code_counts":{"AB":1,"NOT_PROVIDED":12},"marketing_status_counts":{"Prescription":12,"Discontinued":1},"meaning":"raw FDA codes; the therapeutic equivalence code says whether FDA rates a generic as substitutable, and what that means for a given prescription is for a pharmacist or prescriber","products":[{"application":"NDA205552","product_no":"001","te_code":"AB","marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"140MG","untrusted":true}},{"application":"NDA205552","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"70MG","untrusted":true}},{"application":"NDA210563","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"140MG","untrusted":true}},{"application":"NDA210563","product_no":"004","te_code":null,"marketing_status":"Discontinued","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"560MG","untrusted":true}},{"application":"NDA210563","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"280MG","untrusted":true}},{"application":"NDA210563","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"420MG","untrusted":true}},{"application":"NDA217003","product_no":"004","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"140MG","untrusted":true}},{"application":"NDA217003","product_no":"005","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"230MG","untrusted":true}},{"application":"NDA217003","product_no":"002","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"70MG","untrusted":true}},{"application":"NDA217003","product_no":"006","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"420MG","untrusted":true}},{"application":"NDA217003","product_no":"001","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"SUSPENSION;ORAL","untrusted":true},"strength":{"text":"70MG/ML","untrusted":true}},{"application":"NDA217003","product_no":"003","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"CAPSULE;ORAL","untrusted":true},"strength":{"text":"140MG","untrusted":true}},{"application":"NDA217003","product_no":"007","te_code":null,"marketing_status":"Prescription","drug_name":{"text":"IMBRUVICA","untrusted":true},"form":{"text":"TABLET;ORAL","untrusted":true},"strength":{"text":"560MG","untrusted":true}}]},"supply":{"fda_shortage_status_counts":{},"packages_with_a_termination_date":1,"next_package_termination_dates":[],"packages_with_future_termination_date":0,"termination_meaning":"manufacturer-reported last-lot expiry or withdrawal date of one package; other packages and generics can remain"},"trials":{"attribution":"Source: ClinicalTrials.gov","modification_statement":"OmniRx has summarized and trimmed this ClinicalTrials.gov data.","not_an_offer":"A recruiting trial listing is not an offer of free drug and not medical advice; enrollment is decided by the study team.","ingredients":[{"ingredient":{"text":"IBRUTINIB","untrusted":true},"recruiting_interventional_count":30,"not_yet_recruiting_count":6,"by_phase":{"PHASE2":13,"PHASE1/PHASE2":9,"PHASE1":3,"PHASE3":3,"NA":1,"PHASE2/PHASE3":1},"registry_processing_date":"2026-11-06T10:00:05","modifications":"Counts and phase tallies computed here from the full recruiting result set; trials trimmed to the 25 most recently updated, conditions to 3, countries to 10 distinct; no text edited.","recent_trials":[{"nct_id":"NCT05998642","title":{"text":"Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"Canadian Cancer Trials Group","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2024-02-13","link":{"text":"https://clinicaltrials.gov/study/NCT05998642","untrusted":true}},{"nct_id":"NCT06649812","title":{"text":"Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-06","start_date":"2025-10-07","link":{"text":"https://clinicaltrials.gov/study/NCT06649812","untrusted":true}},{"nct_id":"NCT03223610","title":{"text":"Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma","untrusted":true},"phase":["PHASE1","PHASE2"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-05","start_date":"2018-02-09","link":{"text":"https://clinicaltrials.gov/study/NCT03223610","untrusted":true}},{"nct_id":"NCT05106296","title":{"text":"Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer","untrusted":true},"phase":["PHASE1"],"sponsor":{"text":"Theodore S. Johnson","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-11-02","start_date":"2022-02-08","link":{"text":"https://clinicaltrials.gov/study/NCT05106296","untrusted":true}},{"nct_id":"NCT04840602","title":{"text":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","untrusted":true},"phase":["PHASE2"],"sponsor":{"text":"National Cancer Institute (NCI)","untrusted":true},"status":"RECRUITING","last_update_posted":"2026-10-30","start_date":"2022-01-05","link":{"text":"https://clinicaltrials.gov/study/NCT04840602","untrusted":true}}],"fact_id":"5dbc03c2867626c8ea41bd48"}]},"spending":{"reported_under":{"generic":{"text":"Ibrutinib","untrusted":true},"brand":{"text":"Imbruvica","untrusted":true}},"latest_year":2024,"series":[{"year":2020,"gross_spending_usd":2962909303.6,"claims":232858,"beneficiaries":26847,"average_spending_per_claim_usd":12724.103546,"fact_id":"c0d3fba650a78b9e99be7f26"},{"year":2021,"gross_spending_usd":3150225809.6,"claims":230990,"beneficiaries":26044,"average_spending_per_claim_usd":13637.931554,"fact_id":"629e96c8078300aa944ecd73"},{"year":2022,"gross_spending_usd":2853910970.4,"claims":195679,"beneficiaries":22202,"average_spending_per_claim_usd":14584.656352,"fact_id":"d8e7ef72a0a9cdf9d0388d9a"},{"year":2023,"gross_spending_usd":2371893291.7,"claims":152032,"beneficiaries":17100,"average_spending_per_claim_usd":15601.27665,"fact_id":"e9577ee66646e6e43696c419"},{"year":2024,"gross_spending_usd":2266252031.7,"claims":146416,"beneficiaries":15351,"average_spending_per_claim_usd":15478.172001,"fact_id":"6fe2036689aa77e6bbf92e08"}],"rebate_caveat":"CMS's dataset states spending is gross drug cost and does not reflect manufacturers' rebates or other price concessions.","not_a_patient_price":"Spending is the total paid by Medicare, plans and beneficiaries for the drug's claims, not what a patient pays.","meaning":"a drug-level aggregate of Medicare Part D claims for all manufacturers combined; not a formulary, not coverage","source":{"dataset":{"text":"data-year-2024, modified 2026-06-25","untrusted":true},"link":{"text":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-medicaid-spending-by-drug/medicare-part-d-spending-by-drug","untrusted":true}}},"orphan_designation":{"ingredients":[{"ingredient":{"text":"ibrutinib","untrusted":true},"designation_count":17,"approved_count":11,"recent":[{"designated":"2018-02-01","use":{"text":"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma","untrusted":true},"status":"Designated","sponsor":{"text":"Pharmacyclics, LLC","untrusted":true},"approved":false},{"designated":"2017-06-12","use":{"text":"Treatment of pancreatic cancer","untrusted":true},"status":"Designated","sponsor":{"text":"Pharmacyclics, LLC","untrusted":true},"approved":false},{"designated":"2016-06-23","use":{"text":"Treatment of chronic Graft versus Host disease","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Pharmacyclics, LLC","untrusted":true},"approved":true},{"designated":"2016-06-23","use":{"text":"Treatment of chronic Graft versus Host disease","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Pharmacyclics, LLC","untrusted":true},"approved":true},{"designated":"2016-02-02","use":{"text":"Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)","untrusted":true},"status":"Designated/Approved","sponsor":{"text":"Pharmacyclics, LLC","untrusted":true},"approved":true}],"read_on":"2026-11-07T12:00:00.000Z","fact_id":"aa4ecbac879b37fd1cc043d6"}],"reading":"a designation is not an approval and not a statement that the drug treats the condition; status is the FDA database's own"},"medicaid_state_utilization":{"year":2025,"states_with_data":2,"all_states_medicaid_reimbursed_usd":2005435.83,"all_states_medicaid_paid_prescriptions":163,"top_states":[{"state":"KY","medicaid_paid_prescriptions":108,"medicaid_reimbursed_usd":1454672.76,"total_reimbursed_usd":1454672.76,"packages":1,"covers":"all_record_types","fact_id":"9a03aebff8c35a47af970fc5"},{"state":"NJ","medicaid_paid_prescriptions":55,"medicaid_reimbursed_usd":550763.07,"total_reimbursed_usd":912602.93,"packages":1,"covers":"fee_for_service_only","fact_id":"16ef09cb9be55d363e5eb41f"}],"unlabelled_state_code_xx":null,"built_from_facts":2,"facts_fee_for_service_only":1,"older_year_facts_not_used":29,"dataset":"State Drug Utilization Data 2025","read_on":"2026-11-07T22:41:44.201Z","reading":"Medicaid prescriptions and reimbursement by state (CMS State Drug Utilization Data). Reimbursement is before manufacturer rebates: not a net cost, not a patient price. Suppressed managed-care cells make a state figure fee-for-service only. An absent state was suppressed or unreported, not zero.","receipts_note":"a receipt is held for the largest fact behind each state shown; every figure is a sum of the built_from_facts facts, each recomputable from its recorded input hash"}},"receipts":[{"fact_id":"a7bf39d468e25564ea759396","field":"ndc.listing","entity":"ndc:57962000712"},{"fact_id":"9c7774fdf2ed871802a90d04","field":"ndc.listing","entity":"ndc:57962001428"},{"fact_id":"0ef90c8c8c3406fa7252a883","field":"ndc.listing","entity":"ndc:57962007028"},{"fact_id":"99bbee24ddea81f2622d47da","field":"ndc.mfp","entity":"ndc:57962000712"},{"fact_id":"23f1db4323bcdcf006d3e029","field":"ndc.mfp","entity":"ndc:57962001428"},{"fact_id":"69adee4ad259300bd94b3a94","field":"ndc.mfp","entity":"ndc:57962007028"},{"fact_id":"72bc056f0f3ee5c5d9b5c588","field":"drug.generic_entry_earliest","entity":"application:NDA205552"},{"fact_id":"edeb0ed755e351e3c1077e09","field":"drug.patent","entity":"application:NDA205552"},{"fact_id":"1c7422d8a81ef432f47c7deb","field":"drug.exclusivity","entity":"application:NDA205552"},{"fact_id":"273ffd5052bd46666a6e35fc","field":"drug.generic_entry_earliest","entity":"application:NDA210563"},{"fact_id":"1014f51957dd77b0e9361a74","field":"drug.patent","entity":"application:NDA210563"},{"fact_id":"0d8e0aed15f300ac055cc83e","field":"drug.exclusivity","entity":"application:NDA210563"},{"fact_id":"314fd667a1a05f5fe53dc891","field":"drug.generic_entry_earliest","entity":"application:NDA217003"},{"fact_id":"09d2cb69a295b7c9b4f7a1ab","field":"drug.patent","entity":"application:NDA217003"},{"fact_id":"8283004d16a9f179d37e93cf","field":"drug.exclusivity","entity":"application:NDA217003"},{"fact_id":"4094080b1fa4812875667e33","field":"drug.label_event","entity":"application:NDA205552"},{"fact_id":"272f75ee5d3085cd138cb917","field":"drug.label_event","entity":"application:NDA210563"},{"fact_id":"884466885eda792037cc80ab","field":"drug.label_event","entity":"application:NDA217003"},{"fact_id":"4e25f062f05acbb3ee0854fe","field":"drug.label_event","entity":"application:NDA205552"},{"fact_id":"b158d508679ddafa552e06c1","field":"drug.label_event","entity":"application:NDA210563"},{"fact_id":"8d7de8e76c4eaaf632e7b5fb","field":"drug.te_code","entity":"application:NDA205552"},{"fact_id":"2ced50b0ff25d36d29e2bcfb","field":"drug.marketing_status","entity":"application:NDA205552"},{"fact_id":"04b500e4fdf72daf66da0f3e","field":"drug.marketing_status","entity":"application:NDA205552"},{"fact_id":"cb67391ee639f6ffd5db3291","field":"drug.marketing_status","entity":"application:NDA210563"},{"fact_id":"a527149b8adf7b1099d4a837","field":"drug.marketing_status","entity":"application:NDA210563"},{"fact_id":"1f3b56c7089b571a6e533cdb","field":"drug.marketing_status","entity":"application:NDA210563"},{"fact_id":"0c82e578e6ef0e0c8d9cb449","field":"drug.marketing_status","entity":"application:NDA210563"},{"fact_id":"e57ed1c059905094ba6c7fe2","field":"drug.marketing_status","entity":"application:NDA217003"},{"fact_id":"9257fcb19185e81fd0aaca0d","field":"drug.marketing_status","entity":"application:NDA217003"},{"fact_id":"7fed550e2517fc3d6335788b","field":"drug.marketing_status","entity":"application:NDA217003"},{"fact_id":"75f395d0a70b41a220a6c964","field":"drug.marketing_status","entity":"application:NDA217003"},{"fact_id":"5dbc03c2867626c8ea41bd48","field":"drug.trial_access","entity":"drug:ibrutinib"},{"fact_id":"c0d3fba650a78b9e99be7f26","field":"drug.partd_spending","entity":"drug:ibrutinib|imbruvica"},{"fact_id":"629e96c8078300aa944ecd73","field":"drug.partd_spending","entity":"drug:ibrutinib|imbruvica"},{"fact_id":"d8e7ef72a0a9cdf9d0388d9a","field":"drug.partd_spending","entity":"drug:ibrutinib|imbruvica"},{"fact_id":"e9577ee66646e6e43696c419","field":"drug.partd_spending","entity":"drug:ibrutinib|imbruvica"},{"fact_id":"6fe2036689aa77e6bbf92e08","field":"drug.partd_spending","entity":"drug:ibrutinib|imbruvica"},{"fact_id":"aa4ecbac879b37fd1cc043d6","field":"drug.orphan_designation","entity":"drug:ibrutinib"},{"fact_id":"9a03aebff8c35a47af970fc5","field":"ndc.medicaid_state_utilization","entity":"ndc_state:57962042028:KY"},{"fact_id":"16ef09cb9be55d363e5eb41f","field":"ndc.medicaid_state_utilization","entity":"ndc_state:57962042028:NJ"}],"as_of":{"newest_fact_retrieved_at":"2026-11-10T20:02:39.475Z"},"edition":{"id":"2026-11","merkleRoot":"006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6","factCount":212100,"manifestPresent":true},"licence":{"classes":["AMBER","GREEN"],"note":"Source records are public; this compilation is cited with attribution. See the provenance tool for each fact's licence label."},"unknown":[{"code":"NO_DATA","field":"price.ratio","reason":"no package has both a brand-class NADAC price and a negotiated price in force"},{"code":"NO_DATA","field":"recalls","reason":"no FDA enforcement report naming a package of these applications is recorded"},{"code":"NO_DATA","field":"assistance_and_offers","reason":"no assistance program lists this drug and no manufacturer offer naming it is recorded; that does not mean none exists"},{"code":"NO_DATA","field":"policy","reason":"no Federal Register event in the edition names this drug or its programs"},{"code":"NO_DATA","field":"biologic_status","reason":"no biologic application of this drug has a Purple Book status in the edition (a drug that is not a biologic has none)"},{"code":"NO_DATA","field":"payment_limit","reason":"no HCPCS code whose NDC crosswalk names a package of these applications has a Part B payment limit in the edition"},{"code":"NO_DATA","field":"rems","reason":"no REMS@FDA program is tied to these applications in the edition (most drugs have none)"},{"code":"NO_DATA","field":"controlled_schedule","reason":"no DEA schedule entry matched this drug's ingredient in the edition"},{"code":"NO_DATA","field":"safety_communication","reason":"no FDA Drug Safety Communication names this drug's ingredient in the edition"}],"disclaimer":"OmniRx is a reference layer of dated public facts, not clinical advice and not a guarantee of price, coverage or eligibility. Each answer lists the facts it rests on."}